Chemotherapy for PR Positive Breast Cancer: 87 Real Stories

Invasive Ductal Carcinoma: Keely's Patient Story

Patient Info: Keely, 40s

Biomarkers: ER-negative, PR-positive, HER2-negative

Keely completed mastectomy and 6 months of chemotherapy and continues a daily long-term medicine planned for 10 years.

breastcancer.orgRead more →

Stage I hormone-responsive breast cancer treated with breast-conserving surgery and planned chemotherapy story

Patient Info: Anonymized, Female | Stage I

Biomarkers: ER-positive; PR-positive

After breast-conserving surgery with no lymph node spread and hormone-responsive pathology, she chose to add chemotherapy to hormone therapy and radiation to reduce recurrence risk, with chemotherapy scheduled to start on June 25, 2008.

Stage II HR-Positive Invasive Lobular Carcinoma: Eutha's Survivor Story

Patient Info: Eutha, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

Eutha completed clinical-trial immunotherapy, right mastectomy with lymph-node removal, chemotherapy, radiation and reconstruction for Stage II ER-positive, PR-positive, HER2-positive breast cancer, and returned to work and community life; no explicit NED/cancer-free status was provided.

Memorial Sloan KetteringRead more →

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient StoryRead more →

Stage III HR-Positive Invasive Ductal Carcinoma: Stefanie's Survivor Story

Patient Info: Stefanie, Female | Stage III

Biomarkers: ER-positive, PR-positive and HER2-positive

Stefanie completed chemotherapy, breast-conserving surgery, prolonged Herceptin and 30 radiation treatments, then moved into survivorship while still adjusting to the lasting effects of treatment.

The Patient StoryRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Shari's Patient Story

Patient Info: Shari S., Female | Stage IV

Biomarkers: ER-positive, PR-positive and HER2-positive; no inherited cancer mutation was identified

Metastatic Site: Brain; other initial metastatic sites were not named

Systemic imaging after chemotherapy showed no active disease, but brain metastases later required stereotactic radiation. Shari remained stage 4, continued Herceptin every 3 weeks and underwent brain MRI every 3–4 months.

The Patient StoryRead more →

Stage I HR-Positive Invasive Ductal Carcinoma: Amelia's Patient Story

Patient Info: Amelia, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; BRCA negative; Oncotype DX score 22

As of June 2026, Amelia had no evidence of disease after lumpectomy, bilateral mastectomy, TC chemotherapy, and reconstruction, and she remained on tamoxifen.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Doreen's Patient Story

Patient Info: Doreen, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Doreen had completed TCHP chemotherapy with a complete response before surgery and had undergone lumpectomy and radiation for Stage IIA triple-positive breast cancer.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Rach's Patient Story

Patient Info: Rach D., Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Rach described Stage II triple-positive breast cancer treated with fertility preservation, 6 rounds of neoadjuvant TCHP including Herceptin, Zoladex ovarian suppression, and double mastectomy with reconstruction.

The Patient StoryRead more →

Stage I luminal A invasive ductal breast cancer with post-treatment cognitive symptoms

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: ER 100% positive; PR 95% positive; HER2 score 0 / HER2-negative; Ki-67 10%; P63 negative

As of April 2026, the case focused on survivorship after Stage I luminal A breast cancer treatment, with cognitive complaints after chemotherapy and improved MoCA and depression scores after 12 sessions of tDCS; brain metastases had been ruled out.

PubMed CentralRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Janet's Patient Story

Patient Info: Janet Ayala, Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; ATM mutation

After complete pathologic response and completion of HER2-targeted infusions, Janet remained in survivorship-focused ongoing care with estrogen suppression and additional endocrine/targeted therapy planning to reduce recurrence risk.

City of HopeRead more →

Stage IIB breast cancer with severe radiation recall after abemaciclib

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2 1+ / HER2-negative

The flap healed after abemaciclib was stopped and the tissue expander/patch were removed, but her long-term cancer-control and reconstruction outcomes were not yet reported.

PubMed CentralRead more →

Stage III Breast Cancer Treatment Complicated by Coronary Thrombosis

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 25–30%

She achieved complete remission about 12 months after the myocardial infarction and remained in complete oncologic remission at 44 months.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Sian's Survivor Story

Patient Info: Sian Bevans, Female, 50s | Stage II

Biomarkers: Triple-positive

Sian was 11 years past diagnosis, completed 10 years of maintenance medication in May 2025, and reported feeling more like herself; no recurrence was described.

Cleveland ClinicRead more →

Luminal B-like lobular breast cancer: robotic-assisted nipple-sparing mastectomy with 12-month disease-free follow-up

Patient Info: Anonymized, Female, 40s

Biomarkers: ER 90%; PR 100%; HER2-negative; Ki-67 20%; luminal B-like subtype

As of November 2025, she was disease-free 12 months after neoadjuvant taxane-based chemotherapy and single-port robotic-assisted nipple-sparing mastectomy with immediate reconstruction.

PubMed CentralRead more →

HER2-Positive Breast Cancer: Janella's Survivor Story

Patient Info: Janella Bustamante, Female, 40s

Biomarkers: Triple-positive: estrogen-, progesterone- and HER2-fueled breast cancer

As of October 2025, Janella had completed lumpectomy, chemotherapy, radiation and HER2-targeted biological therapy for triple-positive breast cancer and was on follow-up every 3 months; the source describes life after cancer but does not explicitly state NED/cancer-free.

Cleveland ClinicRead more →

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed CentralRead more →

HER2-positive Stage IV breast cancer: T-DM1 extravasation wound healed after multidisciplinary care

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 70% positive; HER2 IHC 3+

Metastatic Site: pelvis

As of October 2025, the T-DM1 extravasation wound had almost fully healed within about 4 weeks, and the patient continued adjuvant T-DM1 through a port; longer cancer-control status was not described.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Njathi, Female, 40s | Stage II

Biomarkers: Triple-positive; ER-positive; PR-positive; HER2-positive

As of October 2025, Jennifer was more than 1 year past treatment for triple-positive Stage IIA breast cancer and had a recent clear MRI.

City of HopeRead more →

Stage IIA male breast cancer: chemotherapy, mastectomy, endocrine therapy, and benign adrenal nodule

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative

Final breast cancer pathology was T1N1M0 / AJCC Stage IIA ER-positive, PR-positive, HER2-negative invasive ductal carcinoma; the suspicious adrenal lesion was removed in June 2025 and proved to be a benign adrenal adenoma.

PubMed CentralRead more →

Breast cancer survivorship complicated by fatal lymphedema-associated necrotizing soft tissue infection

Patient Info: Anonymized, Female, 50s

Biomarkers: Prior breast cancer: ER-positive, PR-positive, HER2-negative

She died after hospital-acquired pneumonia and acute respiratory failure during recovery from severe right-arm lymphedema-associated necrotizing soft tissue infection after prior breast cancer treatment.

PubMed CentralRead more →

Stage IIIB male encapsulated papillary breast cancer: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: ER-positive 100%; PR-positive 100%; HER2-negative / IHC 1+; p63 loss supported encapsulated papillary carcinoma; no neuroendocrine differentiation

Three years after diagnosis, he was clinically doing well without evidence of breast cancer recurrence after mastectomy, radiation, and tamoxifen.

PubMed CentralRead more →

Stage IIB HER2-positive apocrine breast carcinoma treated with chemotherapy, trastuzumab, radiation, and tamoxifen

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER 80%; PR 5%; HER2-positive by HercepTest and FISH; Ki-67 15%; AR testing not performed

At 7 months of follow-up, the patient remained in remission, with no locoregional recurrence or distant metastasis reported.

PubMed CentralRead more →

Stage 3 breast cancer: complete pathological response to chemotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

At 1-year follow-up, she remained free of breast cancer; a thyroid nodule found on CT had no malignancy on fine-needle aspiration.

PubMed CentralRead more →